Home
Products
Learn
About
Pricing
Log In

What are you looking for?

Home
Pricing
Compare AU

Compare VDAL vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Vanguard Diversified All Growth Index ETF

ASX

Buy

Buy

Global X S&P Biotech ETF

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are VDAL and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

VDAL

CURE

Popularity

Low

Low

Pearlers invested

57

78

Median incremental investment

$1,006.75

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$1,050.28

$1,274.70

Average age group

> 35

> 35


Key Summary

VDAL

CURE

Strategy

VDAL.AX was created on 2025-03-04 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified All Growth Index ETF seeks to track the weighted average return of the various indices of the Underlying Funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Vanguard Diversified All Growth Index ETF (100 %)

Natera Inc (2.73 %)

Alnylam Pharmaceuticals Inc (2.65 %)

Vertex Pharmaceuticals Inc (2.64 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.27 %

0.45 %


Key Summary

VDAL

CURE

Issuer

Vanguard

Global X

Tracking index

40% S&P/ASX 300 Index - 29.5% MSCI World ex-Australia Index - 18% MSCI World ex-Australia Index - 7% MSCI World ex-Australia Small Cap Index - 5.5% MSCI Emerging Markets Index - Benchmark TR Net

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.27 %

0.45 %

Price

$48.40

$42.24

Size

N/A

$28.994 million

10Y return

N/A

N/A

Annual dividend/β€Šdistribution yield (5Y)

0.04 %

4.24 %

Market

ASX

ASX

First listed date

04/03/2025

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

VDAL

CURE

Popularity

Low

Low

Pearlers invested

57

78

Median incremental investment

$1,006.75

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$1,050.28

$1,274.70

Average age group

> 35

> 35


Pros and Cons

VDAL

CURE

Pros

  • Lower management fee

  • Higher price growth

  • Higher exposure to US market

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Lower distribution yield

  • Higher management fee

  • Lower price growth

VDAL

CURE

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield